Get notified when ABBV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Special Mandatory Redemption (new) — If the Apogee acquisition is terminated, AbbVie must redeem the Mandatorily Redeemable Notes at 101% of principal, but it may not have sufficient funds and there is no escrow or security for the proceeds.
- No Financial Covenants (new) — The indenture lacks financial covenants and offers limited protection in a highly leveraged transaction or change of control, increasing risk for noteholders.
AbbVie offers senior notes to fund Apogee Therapeutics acquisition; terms not yet set
Filed August 4, 2026 · ~1 min read
Key Changes
-
high
AbbVie is offering multiple series of senior notes, including floating rate and fixed rate notes, but principal amounts and interest rates are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
high
Net proceeds will fund a portion of the cash payment for the acquisition of Apogee Therapeutics and pay related fees; remainder for general corporate purposes, possibly debt repayment.
Use of Proceeds verify on EDGAR → -
high
If the Apogee acquisition is terminated, AbbVie must redeem the Mandatorily Redeemable Notes at 101% of principal plus accrued interest; Long-Term Notes are not subject to this redemption.
The Offering verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PLAY 10-Q) is open in full — no account needed.
Partner
Trade ABBV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify